InflaRx to Report Second Quarter 2025 Results on August 7, 2025
InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, before market opening. No earnings call is planned.
The company specializes in developing therapeutics targeting the complement system, particularly the C5a inflammatory mediator. Their key developments include vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an oral small molecule C5a receptor inhibitor. InflaRx maintains operations in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.
InflaRx (NASDAQ: IFRX), un'azienda biofarmaceutica specializzata in terapie anti-infiammatorie, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025, prima dell'apertura dei mercati. Non è prevista alcuna conference call sugli utili.
L'azienda si concentra sullo sviluppo di terapie che agiscono sul sistema del complemento, in particolare sul mediatore infiammatorio C5a. Tra i loro principali sviluppi figurano vilobelimab, un anticorpo monoclonale anti-C5a somministrato per via endovenosa, e INF904, un inibitore orale del recettore C5a a piccola molecola. InflaRx opera a Jena e Monaco, in Germania, e ad Ann Arbor, Michigan, USA.
InflaRx (NASDAQ: IFRX), una compañía biofarmacéutica centrada en terapias antiinflamatorias, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025, antes de la apertura del mercado. No se ha planificado una llamada de resultados.
La empresa se especializa en el desarrollo de terapias dirigidas al sistema del complemento, especialmente al mediador inflamatorio C5a. Sus desarrollos clave incluyen vilobelimab, un anticuerpo monoclonal intravenoso anti-C5a, y INF904, un inhibidor oral de receptor C5a de pequeña molécula. InflaRx mantiene operaciones en Jena y Múnich, Alemania, y Ann Arbor, Michigan, EE.UU.
InflaRx (NASDAQ: IFRX)는 항염증 치료제에 집중하는 바이오제약 회사로, 2025년 2분기 재무 결과 발표를 2025년 8월 7일 시장 개장 전에 예정하고 있습니다. 실적 발표 컨퍼런스 콜은 계획되어 있지 않습니다.
이 회사는 보체 시스템, 특히 염증 매개체인 C5a를 표적으로 하는 치료제 개발에 전문성을 가지고 있습니다. 주요 개발 제품으로는 정맥주사형 항-C5a 단클론 항체인 vilobelimab과 경구용 소분자 C5a 수용체 억제제인 INF904가 있습니다. InflaRx는 독일 예나와 뮌헨, 미국 미시간주 앤아버에서 운영 중입니다.
InflaRx (NASDAQ : IFRX), une société biopharmaceutique spécialisée dans les thérapeutiques anti-inflammatoires, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 7 août 2025, avant l'ouverture des marchés. Aucun appel aux résultats n'est prévu.
L'entreprise se concentre sur le développement de thérapies ciblant le système du complément, en particulier le médiateur inflammatoire C5a. Parmi ses développements clés figurent vilobelimab, un anticorps monoclonal anti-C5a administré par voie intraveineuse, et INF904, un inhibiteur oral du récepteur C5a de petite molécule. InflaRx opère à Jena et Munich en Allemagne, ainsi qu'à Ann Arbor, Michigan, aux États-Unis.
InflaRx (NASDAQ: IFRX), ein biopharmazeutisches Unternehmen, das sich auf entzündungshemmende Therapeutika spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 7. August 2025 vor Börsenöffnung geplant. Eine Telefonkonferenz zur Gewinnbekanntgabe ist nicht vorgesehen.
Das Unternehmen spezialisiert sich auf die Entwicklung von Therapeutika, die das Komplementsystem, insbesondere den Entzündungsmediator C5a, anvisieren. Zu den wichtigsten Entwicklungen zählen vilobelimab, ein intravenös verabreichtes monoklonales Anti-C5a-Antikörper, und INF904, ein oraler niedermolekularer C5a-Rezeptor-Inhibitor. InflaRx ist in Jena und München, Deutschland, sowie in Ann Arbor, Michigan, USA, tätig.
- None.
- None.
JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) report Q2 2025 earnings?
What are the main products in InflaRx's pipeline?
Will InflaRx hold an earnings call for Q2 2025 results?
Where are InflaRx's main operations located?
What is InflaRx's therapeutic focus?
